RMD · Investment summary · as of 12 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
At $224.84, RMD requires a 2% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 10%.
the GLP-1 dispute is a growth dispute; both margin solves carry double-digit slack
The value rests on an exit multiple of 16.2x, a terminal operating margin of 35% and a 7.9% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Oral GLP-1 approval for an OSA indication solves the persistence problem and new PAP starts turn negative.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | the GLP-1 dispute is a growth dispute; both margin solves carry double-digit slack |
| What do we forecast? | Revenue growth of 10% demonstrated; a terminal operating margin of 35%; an exit multiple of 16.2x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +7.5 percentage points. |
| What is it worth? | Twelve-month target $241.00, +7% from the struck price. Scenario-weighted expected return net of costs +7.4%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 29 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| quarterly from Q1 FY2027 | Global devices revenue growth <= 0% YoY (reported USD) for two… | Neither leg of the condition opposite is met at this date | Global devices revenue growth <= 0% YoY (reported USD) for two consecutive quarters |
| quarterly from Q1 FY2027 | Masks-and-other growth below devices growth for two consecutive… | Neither leg of the condition opposite is met at this date | Masks-and-other growth below devices growth for two consecutive quarters |
| quarterly from Q2 FY2027 (first clean post-close quarter) | Post-divestiture RCS revenue growth below +5% constant-currency for… | Neither leg of the condition opposite is met at this date | Post-divestiture RCS revenue growth below +5% constant-currency for two consecutive quarters |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
Oral GLP-1 approval for an OSA indication solves the persistence problem and new PAP starts turn negative. FY2025 10-K names the escalation; management's own 30-40% one-year GLP-1 persistence concession is what an oral formulation would fix. Path at FY2026 actuals: devices -5%, masks +5%, RCS-remainder hsd -> consolidated ~+1%; margin 33%; 12x exit -> ~$170/share.
Estimated probability 20%, against the 41% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Trim on approach to $241; MANDATORY valuation reassessment at 6.95x EV/NTM-sales (~$290), the 5y-defined median of own forward-multiple history. On approach to the $241.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Oral GLP-1 approval for an OSA indication solves the persistence problem and new PAP starts turn negative. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +7.5 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: oral GLP-1 approval for an OSA indication solves the persistence problem and new PAP starts turn negative. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $197.86, which forces an immediate review.